Compile Data Set for Download or QSAR
Report error Found 22 Enz. Inhib. hit(s) with all data for entry = 11895
TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658040(US20240083896, Example 16 | 1-(2-methyl-4- (triflu...)
Affinity DataIC50: 12.6nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658035(US20240083896, Example 10 | 1-(2-ethyl-3,4- difluo...)
Affinity DataIC50: 31.6nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658045(US20240083896, Example 21 | 3-(5-fluoro-2-meth- yl...)
Affinity DataIC50: 39.8nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658030(US20240083896, Example 5 | 1-(4-fluoro-2- isopropy...)
Affinity DataIC50: 63.1nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658041(US20240083896, Example 17 | 1-(3,4-Difluoro-2-meth...)
Affinity DataIC50: 63.1nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658044(US20240083896, Example 20 | 1-(2-ethyl-4-fluoro- p...)
Affinity DataIC50: 79.4nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658038(US20240083896, Example 14 | 1-(2-ethyl-4-fluoro- p...)
Affinity DataIC50: 79.4nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658028(US20240083896, Example 3 | 6-chloro-1-(4- fluoro-2...)
Affinity DataIC50: 100nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658031(US20240083896, Example 6 | 1-(4-fluoro-2- methylph...)
Affinity DataIC50: 100nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658029(US20240083896, Example 4 | 1-(4-fluoro-2- methylph...)
Affinity DataIC50: 158nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658047(US20240083896, Example 23 | 3-Methyl-4-(1-(2-methy...)
Affinity DataIC50: 200nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658042(US20240083896, Example 18 | 7-chloro-1-(4- fluoro-...)
Affinity DataIC50: 251nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658039(US20240083896, Example 15 | 6-chloro-1-(4-fluoro- ...)
Affinity DataIC50: 251nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658036(US20240083896, Example 11 | 3-(5-fluoro-2- methyl-...)
Affinity DataIC50: 316nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658027(US20240083896, Example 2 | 1-(4-fluoro-2- methylph...)
Affinity DataIC50: 1.00E+3nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658026(US20240083896, Example 1 | 1-(4-Fluoro-2-methylphe...)
Affinity DataIC50: 1.26E+3nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658034(US20240083896, Example 9 | 6-Chloro-1-(4-fluoro-2-...)
Affinity DataIC50: 1.59E+3nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658043(US20240083896, Example 19 | 1-(4-fluoro-2-meth- yl...)
Affinity DataIC50: 3.98E+3nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658032(US20240083896, Example 7 | 1-(4-fluoro-2- methylph...)
Affinity DataIC50: 3.98E+3nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658046(US20240083896, Example 22 | 1-(4-Fluoro-2-methylph...)
Affinity DataIC50: 3.98E+3nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658037(US20240083896, Example 12 | 1-(4-Fluoro-2-methylph...)
Affinity DataIC50: 5.01E+3nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658033(US20240083896, Example 8 | 1-(4-fluoro-2- methylph...)
Affinity DataIC50: 7.94E+3nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent